644 related articles for article (PubMed ID: 12568294)
1. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Georges GE; Storb R
Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
Maris M; Storb R
Immunol Res; 2003; 28(1):13-24. PubMed ID: 12947221
[TBL] [Abstract][Full Text] [Related]
4. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
Carella AM
Hematol J; 2004; 5 Suppl 1():S68-75. PubMed ID: 15079155
[TBL] [Abstract][Full Text] [Related]
6. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
[TBL] [Abstract][Full Text] [Related]
10. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
11. Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Baron F; Beguin Y
J Hematother Stem Cell Res; 2002 Apr; 11(2):243-63. PubMed ID: 11983097
[TBL] [Abstract][Full Text] [Related]
12. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning.
Baron F; Sandmaier BM
Curr Opin Hematol; 2005 Nov; 12(6):435-43. PubMed ID: 16217159
[TBL] [Abstract][Full Text] [Related]
13. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Chaudhry HM; Bruce AJ; Wolf RC; Litzow MR; Hogan WJ; Patnaik MS; Kremers WK; Phillips GL; Hashmi SK
Biol Blood Marrow Transplant; 2016 Apr; 22(4):605-616. PubMed ID: 26409924
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.
Sandmaier BM; Mackinnon S; Childs RW
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):87-97. PubMed ID: 17222778
[TBL] [Abstract][Full Text] [Related]
15. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
Maloney DG
Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
[TBL] [Abstract][Full Text] [Related]
16. Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.
Slavin S; Nagler A; Shapira MY; Aker M; Gabriel C; Or R
J Clin Immunol; 2002 Mar; 22(2):64-9. PubMed ID: 11998894
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders.
Baron F; Storb R
Mol Ther; 2006 Jan; 13(1):26-41. PubMed ID: 16280257
[TBL] [Abstract][Full Text] [Related]
18. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
Baron F; Sandmaier BM
Leukemia; 2006 Oct; 20(10):1690-700. PubMed ID: 16871276
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
20. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.
Slavin S; Nagler A; Aker M; Shapira MY; Cividalli G; Or R
Rev Clin Exp Hematol; 2001 Jun; 5(2):135-46. PubMed ID: 11486652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
